[Clinical effectiveness and tolerance of auranofin in patients with chronic polyarthritis. Results of a multicenter long-term study].
In an open multicenter trial, 90 patients with rheumatoid arthritis were treated with a daily dose of 6 mg auranofin. The duration of the treatment was 12 months. A significant improvement in the following parameters was observed: grip strength, number of swollen and painful joints after the 4th month, blood erythrocyte sedimentation rate decreased significantly after the 2nd month. Of the 90 patients, 56 (62.3%) completed the therapy, in 14 (15.5%) it was discontinued because of side effects and in 8 (8.9%) because of inefficacy. 12 patients (13.3%) stated other reasons for discontinuing the therapy (non compliance). The reported side-effects were mostly gastrointestinal, especially diarrhoea and loose stools. The evaluation of results referring to the duration of the disease shows that patients with a duration of less than 2 years reacted better to the improvement with auranofin therapy than patients with a longer sickness history.
Klein
G
G
Rehabilitationszentrum für rheumatische Erkrankungen und Herz-Kreislaufkrankheiten der Pensionsversicherungsanstalt der Arbeiter, Saalfelden.
Schwann
H
H
Mirtl
B
B
Thumb
N
N
Mayerhofer
F
F
Singer
F
F
Tausch
G
G
Gaismayer
K
K
Rieder
H
H
Hartweger
A
A
D000328:Adult; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001310:Auranofin / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged
D001310:Auranofin
Klinische Wirksamkeit und Verträglichkeit von Auranofin bei Patienten mit chronischer Polyarthritis. Ergebnisse einer multizentrischen Langzeitstudie.